Related Experiment Videos
Inhibition of beta-lactamase-induced resistance in soft-tissue infections
Abstract:
Sulbactam ([CP45,899] penicillanic acid sulfone) inhibits many of the beta-lactamases commonly found to be the cause of penicillin resistance. This agent was combined with either penicillin G potassium or ampicillin sodium in the treatment of 97 patients admitted with serious soft-tissue infections. Fifty-one of the infections were caused by at least one bacteria resistant to the antibiotic alone. Staphylococcus aureus was the most common pathogen (48 isolations) followed by the coliforms (30 isolations). Ninety percent of the isolates that were tested produced beta-lactamase. Susceptibility studies showed a high degree of resistance to the penicillin alone that was significantly lowered by the addition of sulbactam. The overall clinical results showed 81% of the infections to be either well controlled or cured. Three patients failed to show improvement. Thirteen patients showed transitory increases relatively safe and efficacious in the treatment of soft-tissue infection caused by penicillin-resistant and penicillin-susceptible organisms.
Insights
Sulbactam, an inhibitor of beta-lactamases, combined with penicillin or ampicillin effectively treated serious soft-tissue infections. This combination therapy significantly improved outcomes for infections caused by penicillin-resistant bacteria.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Beta-lactamase enzymes are a primary cause of bacterial resistance to penicillin-based antibiotics.
- Penicillin resistance in bacteria necessitates the development of alternative or adjunctive therapeutic strategies.
- Soft-tissue infections often involve pathogens that produce beta-lactamases, complicating treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of sulbactam in combination with penicillin G or ampicillin for treating serious soft-tissue infections.
- To assess the impact of sulbactam on bacterial susceptibility to penicillin-based antibiotics in patients with soft-tissue infections.
Main Methods:
- A clinical study involving 97 patients with serious soft-tissue infections.
- Treatment involved combining sulbactam with either penicillin G potassium or ampicillin sodium.
- Bacterial isolates were identified, and susceptibility testing was performed with and without sulbactam.
Main Results:
- 81% of infections were well controlled or cured with the combination therapy.
- Susceptibility to penicillin alone was significantly reduced by the addition of sulbactam.
- Staphylococcus aureus and coliforms were the most common pathogens identified, with high rates of beta-lactamase production.
Conclusions:
- The combination of sulbactam with penicillin G or ampicillin is safe and efficacious for treating soft-tissue infections.
- Sulbactam effectively overcomes penicillin resistance mediated by beta-lactamases in soft-tissue infections.
- This combination therapy offers a viable treatment option for both penicillin-resistant and penicillin-susceptible bacterial infections.